• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [16861 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Agency for Care Effectiveness (ACE) Tolvaptan for treating autosomal dominant polycystic kidney disease
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating Wolman disease. NICE highly specialised technologies guidance 30
2024     National Institute for Health and Care Excellence (NICE) Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome. NICE highly specialised technologies guidance 31
2024     Agency for Care Effectiveness (ACE) Cervical artificial disc replacement for treatment of patients with cervical disc degenerative disease
2024     Agency for Care Effectiveness (ACE) Continuous glucose monitoring systems for children and adults with type 1 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Lumbar artificial disc replacement for treatment of patients with lumbar disc degenerative disease
2024     Agency for Care Effectiveness (ACE) Radiolucent fixation rods & screws for patients with primary and metastatic spinal tumours
2024     Agency for Care Effectiveness (ACE) Tricuspid transcatheter edge-to-edge repair system for symptomatic severe tricuspid regurgitation
2024     Agency for Care Effectiveness (ACE) FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2024     Agency for Care Effectiveness (ACE) Oxevision for vision-based patient monitoring and management in mental health wards
2024     Agency for Care Effectiveness (ACE) KidneyIntelX for patients with diabetic kidney disease
2024     Agency for Care Effectiveness (ACE) Organ Care System (OCS) Heart System for heart transplantation of marginal brain-death donor hearts or circulatory-death donor hearts
2024     Agency for Care Effectiveness (ACE) RelieVRx for the treatment of chronic lower back pain
2024     Agency for Care Effectiveness (ACE) Canvas Dx to aid the diagnosis of autism spectrum disorder
2024     Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2024     Agency for Care Effectiveness (ACE) Nerivio for the acute and preventive treatment of migraine
2024     Agency for Care Effectiveness (ACE) Transcutaneous afferent patterned stimulation for patients with essential tremor or Parkinsons Disease
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and white British people presenting to emergency services for injury: the stakeholder consultation
2024     Austrian Institute for Health Technology Assessment (AIHTA) Telehealth in diabetes – EU mapping and systematic evaluation of organisational aspects
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in dystonia, dyspareunia, and strabismus]
2024     Austrian Institute for Health Technology Assessment (AIHTA) Threshold values in health economic evaluations and decision-making
2024     Austrian Institute for Health Technology Assessment (AIHTA) Artificial Intelligence in health care with a focus on hospitals: methodological considerations for health technology assessment: a scoping review
2024     Austrian Institute for Health Technology Assessment (AIHTA) Oncological breast cancer care in selected European countries: cross-sectoral cancer care models
2024     Austrian Institute for Health Technology Assessment (AIHTA) Mental health screening of adults in primary care
2024     Scottish Health Technologies Group (SHTG) Digital fracture liaison service
2024     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2024     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2023
2024     Institute for Clinical and Economic Review (ICER) Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024     Institute for Clinical and Economic Review (ICER) Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
2024     Institute for Clinical and Economic Review (ICER) Imetelstat for anemia in myelodysplastic syndrome: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Ensifentrine for the treatment of chronic obstructive pulmonary disease: effectiveness and value
2024     Institute for Clinical and Economic Review (ICER) Midomafetamine-assisted psychotherapy for post-traumatic stress disorder
2024     Institute for Clinical and Economic Review (ICER) Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
2024     Institute for Clinical and Economic Review (ICER) KarXT for schizophrenia
2024     Institute for Clinical and Economic Review (ICER) Sotatercept for pulmonary arterial hypertension
2024     Health Information and Quality Authority (HIQA) A summary of publicly-funded services for fertility preservation for medical reasons in selected countries
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Benefits and risks of emergency departments with or without a co-located primary care driven urgent care center
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Umbilical cord clamping at one minute, allowing stem cell harvesting, compared with delayed cord clamping - infant and maternal outcomes
2024     National Institute for Health and Care Excellence (NICE) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome. NICE diagnostics guidance 62
2024     National Institute for Health and Care Excellence (NICE) Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant. NICE interventional procedures guidance 795
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound subthalamotomy for treating Parkinson's. NICE interventional procedures guidance 797
2024     National Institute for Health and Care Excellence (NICE) MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's. NICE interventional procedures guidance 796
2024     National Institute for Health and Care Excellence (NICE) Bevacizumab gamma for treating wet age-related macular degeneration. NICE technology appraisal guidance 1022
2024     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021
2024     National Institute for Health and Care Excellence (NICE) Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal). NICE technology appraisal guidance 1024
2024     National Institute for Health and Care Excellence (NICE) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2024     National Institute for Health and Care Excellence (NICE) Ublituximab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 1025
2024     National Institute for Health and Care Excellence (NICE) Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2024     NIHR Health Technology Assessment programme Energetic activity for depression in young people aged 13–17 years: the READY feasibility RCT
2024     NIHR Health Services and Delivery Research programme A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study
2024     NIHR Health Services and Delivery Research programme Clinical and cost-effectiveness of first contact physiotherapy for musculoskeletal disorders in primary care: the FRONTIER, mixed method realist evaluation
2024     NIHR Health Technology Assessment programme Cervical ripening at home or in hospital during induction of labour: the CHOICE prospective cohort study, process evaluation and economic analysis
2024     NIHR Health and Social Care Delivery Program Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     NIHR Health Services and Delivery Research programme Strengthening open disclosure in maternity services in the English NHS: the DISCERN realist evaluation study
2024     Penn Medicine Center for Evidence-based Practice (CEP) Urinary catheter exchange prior to sample collection 2024 update
2024     Health Technology Wales (HTW) Non antibiotic antimicrobial anticoagulant catheter locking solutions for the prevention of catheter related complications
2024     Health Technology Wales (HTW) ELF test (Enhanced Liver Fibrosis)
2024     Health Technology Wales (HTW) Robot-assisted benign gynaecological surgery
2024     Health Technology Wales (HTW) Advanced paramedic practitioners
2024     Health Technology Wales (HTW) Digital tools for diabetes management
2024     NIHR Health Services and Delivery Research programme Interpersonal counselling for adolescent depression delivered by youth mental health workers without core professional training: the ICALM feasibility RCT
2024     NIHR Health Technology Assessment programme Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling
2024     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis
2024     NIHR Health and Social Care Delivery Program Exploratory study from an end-of-life research partnership network to improve access for ethnically diverse communities in one region
2024     WorkSafeBC Rest as treatment for adhesive capsulitis: 2024 update
2024     WorkSafeBC Causal association between sprain/strain and myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia
2024     WorkSafeBC Noise-cancelling headphones as treatment for PTSD - 2024 update
2024     WorkSafeBC Association between complex regional pain syndrome, ketamine use, lower urinary tract symptoms and erectile dysfunction
2024     WorkSafeBC Efficacy/effectiveness of nSTRIDE injection in treating patients with knee osteoarthritis
2024     WorkSafeBC Efficacy/effectiveness of axillary nerve block to treat shoulder pain
2024     WorkSafeBC Effectiveness of prolotherapy in rotator cuff tendinopathy
2024     WorkSafeBC COVID-19 and perimyocarditis
2024     WorkSafeBC Effectiveness of botulinum toxin (botox), A or B, in treating painful neuroma: 2024 update
2024     WorkSafeBC Low intensity ultrasound for treating fracture nonunion and short reviews on other bone growth stimulator devices and orthobionomics: second update January 2024
2024     NIHR Health Technology Assessment programme Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
2024     NIHR Health and Social Care Delivery Program Early mental health intervention and supported self-care for LGBTQ+ young people in the UK: a mixed-methods study
2024     NIHR Health Technology Assessment programme Collagenase injection versus limited fasciectomy surgery to treat Dupuytren’s contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation
2024     NIHR Health Technology Assessment programme Point-of-care tests for urinary tract infections to reduce antimicrobial resistance: a systematic review and conceptual economic model
2024     National Institute for Health and Care Excellence (NICE) Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. NICE interventional procedures guidance 794
2024     National Institute for Health and Care Excellence (NICE) Digital technologies for assessing attention deficit hyperactivity disorder (ADHD). NICE diagnostics guidance 60
2024     National Institute for Health and Care Excellence (NICE) Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices. NICE diagnostics guidance 61
2024     National Institute for Health and Care Excellence (NICE) Belzutifan for treating tumours associated with von Hippel-Lindau disease. NICE technology appraisal guidance 1011
2024     National Institute for Health and Care Excellence (NICE) Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia. NICE technology appraisal guidance 1013
2024     National Institute for Health and Care Excellence (NICE) Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1010
2024     National Institute for Health and Care Excellence (NICE) Avapritinib for treating advanced systemic mastocytosis. NICE technology appraisal guidance 1012
2024     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1015
2024     National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024     National Institute for Health and Care Excellence (NICE) Elafibranor for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1016
2024     National Institute for Health and Care Excellence (NICE) Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over. NICE technology appraisal guidance 1019
2024     National Institute for Health and Care Excellence (NICE) Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. NICE technology appraisal guidance 1018
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024     National Institute for Health and Care Excellence (NICE) Eplontersen for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 1020
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Molecular characterization of central nervous system tumors by (next-generation sequencing, NGS). Evaluation of diagnostic and prognostic utility and implementation considerations]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Indications for urinary catheterization in sedated patients
2024     Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024     NIHR Health Technology Assessment programme Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
2024     NIHR Health and Social Care Delivery Program The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2024     NIHR Health and Social Care Delivery Program Challenges and guidance for implementing social distancing for COVID-19 in care homes: a mixed methods rapid review
2024     NIHR Health and Social Care Delivery Program Understanding and improving the quality of primary care for people in prison: a mixed-methods study